Clinical Assessment of Voriconazole Self Nano Emulsifying Drug Delivery System Intermediate Gel

NCT ID: NCT04110860

Last Updated: 2019-10-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-02-15
• Study Completion Date: 2018-06-30

Brief Summary

Clinical study for the developed voriconazole self nano emulsifying drug delivery system intermediate gel was conducted on 30 patients with tinea versicolor infection.

Detailed Description

The clinical work has been carried out in accordance with The Code of Ethics of the World Medical Association for experiments involving humans. The study was conducted on 30 patients (10 to 60 years old) with tinea versicolor attending the dermatology department outpatient clinic of Minia University Hospital. Local institutional review board approval was obtained for this study (ethical approval number is 24/18). Pregnant or lactating females and Immunocompromized patients. The patients were then divided into 3 groups, placebo group, group A and group B, consisting of 10 patients each. The placebo group received unmedicated formulation, Group A received the medicated formulation once daily and group B were treated twice daily. An informed consent has been obtained from all patients enrolled in the study for photography and treatment. History and general local examination were performed for all patients.The patients were clinically examined under normal light and using wood's lamp and cello-tape test was performed to confirm infection after determining the type of infection and in some cases scrapes were taken to detect infection in clinically indefinite cases and stained using potassium hydroxide 20% then examined for presence of fungal elements. Treatment was performed by applying the gel once or twice daily until full recovery was achieved with follow up once a week to reassess the condition. The clinical improvement of the patients, patient satisfaction and length of treatment were assessed. It was rated by both patient and physician as excellent, good, fair or poor according to the following criteria. Excellent: both the patient and the physician agreed that the result was satisfactory. Good: the result although acceptable was not quite up to expectations, but the physicians were pleased with the outcome. Fair: the improvement was evaluated by both the patient and the physician to be less than expected but still with some improvement. Poor: unsatisfactory results to the patient and /or the physician. All adverse effects were checked during study.High resolution digital photographs were taken for lesions of all patients using identical camera folder setting before starting treatment, on each follow up visit and after complete recovery. Clinical improvement was evaluated by physicians. The criteria for evaluations using a quartile grading scale were: 0=no improvement. 1=mild (percent improvement, less than 25%), 2=moderate (percent improvement 25-49%), 3=good (percent improvement 50-74%), 4=excellent (percent improvement equal to or more than 75%). In addition, a patient satisfaction score was rated using the following scale, A. satisfied, B.

Conditions

Tinea Versicolor

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

once daily application

the gel is applied to the affected areas once daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.

Group Type: EXPERIMENTAL

voriconazole gel once daily

Intervention Type: DRUG

voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily

twice daily application

the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.

Group Type: EXPERIMENTAL

voriconazole gel twice daily

Intervention Type: DRUG

voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily

placebo

the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DRUG

the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, voriconazole, is not added then applied twice daily in the same manner

Interventions

voriconazole gel once daily

voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily

Intervention Type: DRUG

voriconazole gel twice daily

voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily

Intervention Type: DRUG

placebo

the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, voriconazole, is not added then applied twice daily in the same manner

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Tinea Versicolor infection

Exclusion Criteria

• concomitant treatment with other medications for the same condition being studied, TVC.
• pregnancy
• lactation
• immunocompromised patients

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sara Botros

OTHER

Sponsor Role: lead

Responsible Party

Sara Botros

demonstrator

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Sara R Botros, bachelor of clinical pharmacy

Role: PRINCIPAL_INVESTIGATOR

Minia University

Locations

Minia University hospital

Minya, Minya Governorate, Egypt

Countries

Egypt

Other Identifiers

VCZSaraSNEDDS

Identifier Type: -

Identifier Source: org_study_id